GlassScriptPhysician profile
Uzair Hamid
NPI 1578147351
$1,323.22
in general payments reported to CMS, 2019-2025
5 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $727 · Food and Beverage: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $726.55 |
| Food and Beverage | $596.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,250.10 | 2025 | Vns Therapy |
| Abbvie INC. | $24.92 | 2025 | |
| Ucb, INC. | $18.18 | 2025 | Nayzilam |
| Sk Life Science, INC. | $15.44 | 2025 | |
| Neurelis, INC. | $14.58 | 2025 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzair Hamid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.